Drospirenone, a new progestogen, for postmenopausal women with hypertension

Drugs and Aging

Volumn 24, Issue 6, 2007, Pages 453-466

  Mallareddy, Madhavi ^a   Hanes, Vladimir ^b   White, William B ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b Bayer Healthcare Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CYPROTERONE; DESOGESTREL PLUS ETHINYLESTRADIOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ENALAPRIL; ESTRADIOL; ESTROGEN; ESTROGEN PLUS PROGESTOGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVONORGESTREL; LIPOPROTEIN; MEDROXYPROGESTERONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; PLACEBO; POTASSIUM; PROGESTERONE; SODIUM; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WATER;

ABDOMINAL OBESITY; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN THERAPY; HORMONAL THERAPY; HUMAN; HYPERTENSION; KIDNEY FAILURE; MENOPAUSAL SYNDROME; MENOPAUSE; MONOTHERAPY; NATRIURESIS; NONHUMAN; PATHOGENESIS; POTASSIUM BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SODIUM RETENTION; UTERUS; WATER RETENTION; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; ALDOSTERONE ANTAGONISTS; ANDROSTENES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERTENSION; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 34250830245     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724060-00002     Document Type: Review

References (56)

1. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358 (9290): 1305-15
2. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13
3. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
4. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-13
5. Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular risk factors in men versus women. J Gend Specif Med 2002; 5: 27-37
6. Staessen JA, Ginocchio G, Thijs L, et al. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens 1997; 11: 507-14
7. Zanchetti A, Facchetti R, Cesana GC, et al. SIMONA participants. Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. J Hypertens 2005; 23: 2269-76
8. Staessen J, Bulpitt CJ, Fagard R, et al. The influence of menopause on blood pressure. J Hum Hypertens 1989; 3 (6): 427-33
9. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women's Health Initiative. Hypertension 2000; 36 (5): 780-9
10. Whyte JL, Lapuerta P, L'Italien GJ, et al. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J Clin Hypertens 2001; 3 (4): 211-6
11. Hernandez Schulman I, Raij L. Salt sensitivity and hypertension after menopause: role of nitric oxide and angiotensin II. Am J Nephrol 2006; 26: 170-80
12. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 2004; 43 (5): 918-23
13. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 2001; 37 (5): 1199-208
14. Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. Hypertension 2005; 46 (2): 249-54
15. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88 (6): 2404-11
16. Kaaja RJ, Poyhonen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2006; 24 (1): 131-41
17. Milewicz A, Tworowska U, Demissie M. Menopausal obesity: myth or fact? Climacteric 2001; 4 (4): 273-83
18. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-36
19. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321-31
20. Mesch VR, Boero LE, Siseles NO, et al. Metabolic syndrome throughout the menopausal transition: influence of age and menopausal status. Climacteric 2006; 9: 40-8
21. Hill K. The demography of menopause. Maturitas 1996; 23: 113-27
22. Wysowski DK, Governale LA. Use of menopausal hormones in the United States, 1992 through June 2003. Pharmacoepidemiol Drug Saf 2005; 14: 171-6
23. Skouby SO, Al-Azzawi F, Barlow D, et al. European Menopause and Andropause Society. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005; 51 (1): 8-14
24. North American Menopause Society. Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004; 11: 589-600
25. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-33
26. Anderson GL, Limacher M, Assaf AR, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291 (14): 1701-12
27. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006; 166 (9): 1027-32
28. Stefanick ML, Anderson GL, Margolis KL, et al. WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295 (14): 1647-57
29. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000; 132 (9): 689-96
30. Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism. Gend Med 2005; 2 Suppl. A: S18-27
31. Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68: 891-905
32. Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1999; 761: 311-35
33. Pollow K, Juchem M, Elger W, et al. Dihydrospirorenone (ZK30595): a novel synthetic progestagen -characterization of binding to different receptor proteins. Contraception 1992; 46: 561-74
34. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61 (4): 166-71
35. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80 (6): 1816-21
36. Arias-Loza PA, Hu K, Schafer A, et al. Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension 2006; 48: 994-1001
37. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62 (1): 29-38
38. Rosenbaum P, Schmidt W, Helmerhorst FM, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur J Contracept Reprod Health Care 2000; 5: 16-24
39. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000; 5 (1): 25-34
40. Foidart JM, Wuttke W, Bouw GM, et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124-34
41. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 2003; 8: 37-51
42. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models. Contraception 1995; 51: 99-110
43. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzneimittelforschung 1985; 35: 459-71
44. Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837-42
45. Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7: 189-96
46. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12: 716-27
47. Preston RA, Alonso A, Panzitta D, et al. Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002; 15: 816-22
48. Preston RA, White WB, Pitt B, et al. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18: 797-804
49. White WB, Pitt B, Preston RA, et al. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005; 112: 1979-84
50. White WB, Hanes V, Chauhan V, et al. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48: 246-53
51. Preston RA, Norris PM, Alonso AB, et al. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007; 14: 1-7
52. Mancia G, Omboni S, Parati G, et al. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995; 8: 311-5
53. White WB. Utility of ambulatory blood pressure monitoring in the assessment of antihypertensive therapies. In: White WB, editor. Blood pressure monitoring in cardiovascular medicine. Totowa (NJ): Humana Press, 2000: 273-98
54. White WB, Carr AA, Krause S, et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003; 92: 38-42
55. Schurmann R, Blode H, Benda N, et al. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J Clin Pharmacol 2006; 46: 867-75
56. Warming L, Ravn P, Nielsen T, et al. Safety and efficacy of drospirenone used in a continuous combination with 17-beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004; 7: 103-11